Search results for "Urine"

showing 10 items of 924 documents

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic …

2007

SummaryTreatment of relapsed or refractory autoimmune mediated haemolytic syndromes, such as autoimmune haemolytic anaemia (AIHA) and thrombotic thrombocytopenic purpura (TTP), represents a therapeutic challenge. Here we report on our experience with the monoclonal anti-CD20 antibody rituximab (R) compared to standard treatment in these diseases. Patients with non-familialTTP orAIHA and no underlying malignancy were included in our analysis. Safety and efficacy of R-treatment were compared to results obtained in standard treatment approaches. Altogether, 27 patients were analyzed, comprising 15 patients withTTP and 12 patients with AIHA. The patients’ average age at the time of diagnosis wa…

AdultMalemedicine.medical_specialtyTime FactorsThrombotic thrombocytopenic purpuraSalvage therapyGastroenterologyDisease-Free SurvivalAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRecurrenceMedian follow-upGermanyhemic and lymphatic diseasesInternal medicinemedicineHumansImmunologic FactorsProgression-free survivalAgedRetrospective StudiesSalvage TherapyPurpura Thrombocytopenic Idiopathicbusiness.industryStandard treatmentAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeDrug Therapy CombinationFemaleRituximabAnemia Hemolytic AutoimmuneRituximabbusinessFollow-Up Studiesmedicine.drugThrombosis and Haemostasis
researchProduct

Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria pati…

2002

Background: The recovery of mediator metabolites from urine has the potential to provide a rapid, safe, and easily available index of release of mediators. We aimed to determine urinary metabolites of both histamine and leukotrienes (LTs) in patients affected by chronic urticaria (CU). Methods: Twenty patients with CU were studied. They were selected on the basis of double-blind placebo-controlled challenge (DBPC) with acetyl salicylic acid (ASA) and food additives. Ten patients (group B) were negative to both challenges. Ten patients (group C) presented urticaria and/or the appearance of angioedema during or 24 h after challenge, with reactions to ASA (five patients) or food additives (fiv…

AdultMalemedicine.medical_specialtyTime FactorsUrticariaUrinary systemImmunologyMethylhistamineProvocation testAdministration OralUrinePlaceboGastroenterologyBronchoconstrictor AgentsDrug HypersensitivityExcretionchemistry.chemical_compoundDouble-Blind MethodSodium BenzoateInternal medicineSodium GlutamatemedicineHumansSulfitesImmunology and AllergyCyclooxygenase InhibitorsTartrazineLeukotriene E4CreatinineAspirinDose-Response Relationship DrugAngioedemabusiness.industryMethylhistaminesMiddle AgedEndocrinologyItalychemistryChronic DiseaseFemaleFood AdditivesControlled Clinical Trials as Topicmedicine.symptombusinessBiomarkersAllergy
researchProduct

Urine Testing During Treatntent Predicts Cocaine Abstinence

2010

The objective of this study was to analyze the influence of the variables that predict cocaine abstinence on an outpatient program for the treatment of addiction to this substance. Participants were 80 patients (85% men and 15% women) selected at random from those receiving treatment at a Spanish health service outpatient unit. For detecting the predictor variables the authors carried out a chi-square automatic interaction detection (CHAID) analysis. Logistic regression analysis and discriminant analysis were performed to estimate the probability of abstinence according to/using the predictor variables detected by CHAID analysis. Abstinence rate after six months of treatment was 37.5%. The …

AdultMalemedicine.medical_specialtyTime Factorsmedia_common.quotation_subjectMedicine (miscellaneous)Logistic regressionUrine testingCocaine-Related DisordersCocaineInternal medicineAmbulatory CareSecondary PreventionmedicineHumansGeneral Psychologymedia_commonChi-Square DistributionAddictionModels TheoreticalAbstinenceLinear discriminant analysismedicine.diseaseCHAIDSubstance Abuse DetectionSubstance abuseLogistic ModelsSpainObjective testFemalePsychologyClinical psychologyJournal of Psychoactive Drugs
researchProduct

Variation of serum and urinary neutrophil gelatinase associated lipocalin (NGAL) after strenuous physical exercise.

2012

AbstractStrenuous exercise may trigger acute complications, such as exertional rhabdomyolysis and gastrointestinal complaint. As less is known about the potential renal impairment after long distance running, we assessed creatinine and neutrophil gelatinase associated lipocalin (NGAL) in serum (sNGAL) and urine (uNGAL) before and after an ultramarathon.The study population consisted of 16 trained male athletes who ran a 60 km ultramarathon. Blood and spot urine samples were collected 20 min before and immediately after the run. Creatinine was assessed by Jaffe assay on Beckman Coulter AU5800 and renal function was expressed as estimated glomerular filtration rate (eGFR) by MDRD formula. NGA…

AdultMalemedicine.medical_specialtyUrinary systemClinical BiochemistryUrologyRenal functionPhysical exerciseUrineCreatinine; neutrophil gelatinase associated lipocalin (NGAL); physical exercise; sportsLipocalinchemistry.chemical_compoundLipocalin-2physical exerciseProto-Oncogene ProteinsmedicineHumansExerciseCreatininebusiness.industryBiochemistry (medical)Acute kidney injuryneutrophil gelatinase associated lipocalin (NGAL)General MedicineAcute Kidney InjuryMiddle Agedmedicine.diseaseLipocalinschemistryCreatinineExertional rhabdomyolysissportsbusinessAcute-Phase ProteinsGlomerular Filtration RateClinical chemistry and laboratory medicine
researchProduct

Blood and urinary abnormalities induced during and after 24-hour continuous running: A case report

2016

In this reported clinical case, a healthy and well-trained male subject [aged 37 years, maximal oxygen uptake (V[Combining Dot Above]O2max) 64 mL·kg·min] ran for 23 hours and 35 minutes covering 160 km (6.7 km/h average running speed). The analysis of hematological and biochemical parameters 3 days before the event, just after termination of exercise, and after 24 and 48 hours of recovery revealed important changes on muscle and liver function, and hemolysis. The analysis of urine sediments showed an increment of red and white blood cells filtrations, compatible with transient nephritis. After 48 hours, most of these alterations were recovered. Physicians and health professionals who monito…

AdultMalemedicine.medical_specialtyUrinary systemPhysiologyPhysical Therapy Sports Therapy and RehabilitationUrine030204 cardiovascular system & hematologyHemolysisRunning03 medical and health sciences0302 clinical medicineAtletamedicineHumansOrthopedics and Sports MedicineMuscle SkeletalPathologicalNephritisbusiness.industryMedicina deportivaVO2 max030229 sport sciencesAtletasmedicine.diseaseHemolysisSurgeryLiverClinical caseLiver functionbusinessNephritisBiomarkers
researchProduct

Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes.

2005

: Background: Splenic marginal zone lymphoma (SMZL) is an infrequent B-cell neoplasm that pursues an indolent course. Signs and symptoms, mostly related to hypersplenism, are successfully managed by splenectomy. However, the therapy of patients who are not fit for a surgical procedure or who relapse after splenectomy, is still an unsettled issue. Patients and methods: We report a phase-II study on 16 patients with SMZL, three therapy naive and 13 pretreated, all showing systemic symptoms or progressive worsening of peripheral cytopenia, who were treated with pentostatin at a dose of 4 mg/m2 every other week for 6–10 wk. In relapsed patients, the median interval between diagnosis and treatme…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentSplenectomyPurine analogueDrug Administration SchedulemedicinePentostatinHumansProgression-free survivalSplenic marginal zone lymphomaLymphocytesAgedCytopeniaDeoxycoformycinbusiness.industrySplenic NeoplasmsRemission InductionNeoplasms Second PrimaryHematologyGeneral MedicineLymphoma B-Cell Marginal ZoneMiddle Agedmedicine.diseaseSMZLSurvival AnalysisSurgerysplenic marginal zonelymphomaDeoxycoformycinFemaleSplenic LymphomabusinessPentostatinvillous lymphocytesmedicine.drugEuropean journal of haematology
researchProduct

Immunologic effects of rituximab on the human spleen in immune thrombocytopenia

2011

Abstract Immune thrombocytopenia (ITP) is an autoimmune disease with a complex pathogenesis. As in many B cell–related autoimmune diseases, rituximab (RTX) has been shown to increase platelet counts in some ITP patients. From an immunologic standpoint, the mode of action of RTX and the reasons underlying its limited efficacy have yet to be elucidated. Because splenectomy is a cornerstone treatment of ITP, the immune effect of RTX on this major secondary lymphoid organ was investigated in 18 spleens removed from ITP patients who were treated or not with RTX. Spleens from ITP individuals had follicular hyperplasia consistent with secondary follicles. RTX therapy resulted in complete B-cell de…

AdultMalemedicine.medical_treatmentImmunologySplenectomySpleenT-Lymphocytes RegulatoryBiochemistryAntibodies Monoclonal Murine-DerivedImmune systemimmune system diseaseshemic and lymphatic diseasesHumansImmunologic FactorsMedicineImmunobiologyAgedAutoimmune diseaseB-LymphocytesPurpura Thrombocytopenic Idiopathicbiologybusiness.industryCell BiologyHematologyMiddle AgedTh1 Cellsmedicine.diseaseLymphatic systemmedicine.anatomical_structureImmunologyMonoclonalbiology.proteinFemaleRituximabAntibodyRituximabbusinessSpleenmedicine.drugBlood
researchProduct

Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in German…

2013

Objective The objective of this article is to evaluate the safety and clinical outcome of rituximab treatment in systemic lupus erythematosus (SLE) patients refractory to standard of care therapy in a real-life setting in Germany. Methods The GRAID registry included patients with different autoimmune diseases who were given off-label treatment with rituximab. Data on safety and clinical response were collected retrospectively. In SLE patients, clinical parameters included tender and swollen joint counts, fatigue, myalgia, general wellbeing, Raynaud’s and the SLEDAI index. Laboratory tests included dsDNA antibody titres, complement factors, hematologic parameters and proteinuria. Finally, th…

AdultMalemyalgiamedicine.medical_specialty610 MedizinCohort StudiesAntibodies Monoclonal Murine-DerivedRheumatologyRefractoryInternal medicineHumansLupus Erythematosus SystemicMedicineIn patientskin and connective tissue diseasesRetrospective Studiesddc:610Proteinuriabusiness.industryOff-Label UseSystemic lupus erythematosus; rituximab; efficacy; safety;Blymphocytes; cohort studiesDiscontinuationCohortPhysical therapyFemaleRituximabmedicine.symptomRituximabbusinessCohort studymedicine.drugLupus
researchProduct

Urine cadmium levels and albuminuria in a general population from Spain: A gene-environment interaction analysis

2017

Background: The interaction of cadmium with genes involved in oxidative stress, cadmium metabolism and transport pathways on albuminuria can provide biological insight on the relationship between cadmium and albuminuria at low exposure levels. Objectives: We tested the hypothesis that specific genotypes in candidate genes may confer increased susceptibility to cadmium exposure. Methods: Cadmium exposure was estimated by inductively coupled plasma mass spectrometry (ICPMS) in urine from 1397 men and women aged 18–85years participating in the Hortega Study, a representative sample of a general population from Spain. Urine albumin was measured by automated nephelometric immunochemistry. Abnorm…

AdultMalerac1 GTP-Binding Protein0301 basic medicinemedicine.medical_specialtyAdolescentPopulationchemistry.chemical_elementUrine010501 environmental sciences01 natural sciencesYoung Adult03 medical and health scienceschemistry.chemical_compoundInternal medicineDiabetes mellitusPrevalencemedicineAlbuminuriaHumanseducationCation Transport Proteinslcsh:Environmental sciencesAged0105 earth and related environmental sciencesGeneral Environmental Sciencelcsh:GE1-350Aged 80 and overCreatinineCadmiumeducation.field_of_studybusiness.industryOdds ratioMiddle Agedmedicine.diseaseOxidative Stress030104 developmental biologyEndocrinologychemistrySpainCreatinineAlbuminuriaEnvironmental PollutantsFemaleGene-Environment Interactionmedicine.symptombusinessCadmiumKidney diseaseEnvironment International
researchProduct

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

2011

Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting. Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune…

AdultNephrologyrituximab; autoimmune diseasesmedicine.medical_specialtyHealth StatusImmunologyDrug ResistanceAutoimmune DiseasesDrug HypersensitivityAntibodies Monoclonal Murine-Derived03 medical and health sciences0302 clinical medicineRheumatologyimmune system diseaseshemic and lymphatic diseasesGermanyInternal medicinemedicineHumansImmunology and Allergyddc:610RegistriesRetrospective Studies030203 arthritis & rheumatologyAutoimmune diseasebusiness.industryRetrospective cohort studymedicine.diseaseRheumatology3. Good healthLymphomaPemphigusTreatment OutcomePatient SatisfactionAntirheumatic AgentsRheumatoid arthritisImmunologyRituximabRituximabbusinessImmunosuppressive Agents030217 neurology & neurosurgeryResearch ArticleFollow-Up Studiesmedicine.drugArthritis Research & Therapy
researchProduct